ZBIO Zenas BioPharma, Inc. Common Stock

71

[ ] | [ ]

NASDAQ | Common Stock

Price
$7.80
Decreased by -7.47%
Dollar volume (20D)
1.70 M
ADR%
10.56
Shares float
0.00
Shares short
3.74 M [N/A%]
Shares outstanding
0.00
Market cap
N/A
Beta
N/A
Price/earnings
N/A
20D range
6.54 9.82
50D range
5.83 9.82
200D range
5.83 26.25

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies.

Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind both CD19 and Fc"RIIb for the treatment of several I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.

The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody.

Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023.

The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Feb 26, 25 -1.26 -
Nov 12, 24 -0.92 -
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 24 5.00 M
Increased by +N/A%
-52.60 M
Decreased by -113.95%
Decreased by -1.05 K%
Decreased by N/A%
Sep 30, 24 0.00
Decreased by -100.00%
-38.61 M
Decreased by -208.42%
Decreased by N/A%
Decreased by N/A%
Jun 30, 24 0.00
Decreased by N/A%
-37.98 M
Decreased by -30.74%
Decreased by N/A%
Decreased by N/A%
Mar 31, 24 0.00 - -27.80 M -
Decreased by N/A%
-
Dec 31, 23 0.00 - -24.59 M -
Decreased by N/A%
-
Sep 30, 23 50.00 M - 35.61 M -
Increased by +71.22%
-
Jun 30, 23 0.00 - -29.05 M -
Decreased by N/A%
-
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY